LUND, Sweden, March 10, 2022 /PRNewswire/ -- Immunovia AB (publ) today announced that the Annual Report for 2021 has been published.
The annual report can be downloaded in pdf format and is available on Immunovia's website: https://investor.immunovia.com/financial-reports/.
For more information, please contact:
Tobias Bülow
Senior Director Investor Relations and Corporate Communications
Email: tobias.bulow@immunovia.com
Tel: +46 736 36 35 74
This is information that Immunovia AB (publ) is obliged to make public pursuant to the Securities Market Act. The information was submitted for publication at 16:45 CET on March 10, 2022.
About Immunovia
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray PanCan-d started in August 2021 in the USA and IMMray PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/immunovia-ab/r/immunovia-publishes-the-annual-report-for-2021,c3522610
The following files are available for download:
https://mb.cision.com/Main/13121/3522610/1546899.pdf | Annual report (PDF) |
